Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
As he did following last month’s Las Vegas massacre of 58 people, Trump resisted any discussion of gun control during a news conference in Tokyo, where he was beginning his first presidential trip to Asia. Instead, Trump characterized the shooting as a “mental health problem at the highest level.” Yet White House officials said Trump is unlikely to call for a specific policy response, as he did after last week’s Islamic State group-inspired truck attack, which killed eight people in New York City. Devin Kelley, the Texas gunman, was discharged from the Air Force several years ago for assaulting his spouse and a child, the Air Force said. “This was a very — based on preliminary reports — a very deranged individual. A lot of problems over a long period of time,” Trump said when asked about the shooting as he and Japanese Prime Minister Shinzo Abe held a joint news conference. Trump’s more muted response to gun violence contrasts with his swift call for legislative and military action following the Oct. 31 truck attack in New York City. Within hours of a rental truck ramming through a crowded bicycle path and into a school bus, Trump called for Congress to “immediately” repeal the diversity visa lottery program that suspect Sayfullo Saipov, an Uzbekistan citizen, used to enter the country in 2010. Trump also claimed that the U.S. had already stepped up its retaliation against the Islamic State group after the attack. “We are hitting them 10 times harder,” he said Friday. After the Las Vegas shooting, Trump and aides said it was inappropriate to consider a policy response while people were still grieving. Despite days later suggesting openness to outlawing the bump stock device that allowed Las Vegas shooter Stephen Paddock to fire at near-automatic rates, the Trump administration has shown no signs of urgency. “He has asked that that process be reviewed, and we’re waiting on some of the details of that to take place,” White House Press Secretary Sarah Sanders said Oct. 27 when asked about bump stocks. “But a decision hasn’t been finalized on that. ” Trump, who supported gun control before reversing his position to enter the Republican presidential primary, courted the National Rifle Association’s endorsement in 2016, and earlier this year became the first president in three decades to speak at the gun group’s annual convention. In February, Trump signed legislation reversing an Obama-era regulation that would have made it harder for Americans with mental illnesses to buy a gun. Under the Obama rule, the Social Security Administration would have been required to send in the names of beneficiaries with mental impairments who needed a third party to manage their financial affairs. The rule would have affected an estimated 75,000 beneficiaries who would have been added to the national background check database. The attack happened in South Texas on Sunday morning when a man dressed in black tactical-style gear and armed with an assault rifle opened fire inside a Baptist church in a small community, killing 26 people and wounding 20 others in the deadliest mass shooting in state history. As Kelley left the scene, authorities said, he was confronted by an armed resident. Kelley later was found dead in his vehicle. Trump said, “Fortunately somebody else had a gun that was shooting in the opposite direction, otherwise it (wouldn’t) have been as bad as it was. It would have been much worse.” Investigators believe Kelley shot himself. ___ Associated Press writers Kevin Freking, Catherine Lucey and Darlene Superville in Washington contributed to this report.

Ex Output:
Trump: Texas mass shooting is about mental health, not guns.


Ex Input:
The story makes clear the “big unknown” remains the price and “how much people are willing to spend to cut a day or so off of a bout of flu.” The story reports that Genentech, the drug’s manufacturer, said it’s too early to comment on the drug’s U.S. price. The story also notes that in Japan, where the drug was invented, it “sells for the equivalent of about $43.50.” The story uses terms like “a little more than a day” and “nearly a day” and “substantially” to describe the drug’s reduction in flu symptoms, fever, and coughing and sneezing, respectively. It does not explain, as the news release does, that: “Similar efficacy results were seen between baloxavir marboxil and [Tamiflu] in relation to duration of symptoms and fever reduction.” In other words, on the symptom front, both drugs were the same. According to the news release, a difference was seen in the length of time the virus was shed from the body (presumably through coughing and sneezing): 24 hours for baloxavir marboxil verses 72 hours for Tamiflu. The news release also states that there was also a difference seen in the level of virus in the nose and throat, but it provides no precise numbers. It is not known whether this benefit translates into less infection transmission, and the story should have made that clear. The news release issued by Genentech about the FDA’s decision to grant priority review describes baloxavir marboxil’s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu. The STAT News story does not mention any potential harms. This evidence comes from the randomized phase III Capstone-1 study the FDA will review, which included 1,436 people in the US and Japan. It excluded people older than 64. The news story does not note this exclusion, nor does it state a key problem with this study: It has never been published in a peer-reviewed journal (instead, a study abstract was released as part of ID Week 2017). This means the full data analysis has never been seen by anyone other than the researchers. We explained why this is important in February 2018, when we discussed news coverage of the drug’s approval in Japan. The 2017-2018 flu season was the worst the US had experienced in nearly a decade. The flu impacted the entire country, and was responsible for 172 pediatric deaths. The news article did not use these or any other flu-related statistics to increase fear about the flu and, in turn, the need for this medication. The article includes two sources: Mark Eisner, Genentech’s VP of product development for immunology, infectious diseases and ophthalmology and Richard Webby, head of the World Health Organization’s influenza collaborating center at St. Jude Children’s Research Hospital in Memphis. Eisner’s affiliation with Genentech, the drug’s manufacturer, is clearly noted. Webby does not appear to have any conflicts of interest. The article would have been stronger if it had included a third source who commented on what–if anything–is known about whether reducing the duration of symptoms leads to reduced levels of transmission that result in fewer people contracting the flu and fewer deaths. The story explains that the only other drug approved to treat the flu is Tamiflu, which is not widely used. The writer explains that both drugs need to be taken within 48 hours of symptom onset and that baloxavir marboxil is a single one-time dose, while Tamiflu must be taken twice daily for five days. It is clear from the story that the FDA is expected to decide by the end of the year whether to approve this new flu medication. The story explains that it’s been more than 20 years since a new class of flu drug has been developed and marketed. (It is available in Japan.) The catalyst for the story was a news release issued by Genentech about the FDA granting priority review of baloxavir marboxil, but the story does not use direct quotes from the news release.

Ex Output:
A flu drug — shown to reduce the duration of symptoms — could upend treatment in U.S.


Ex Input:
"Harrowing images of wooden caskets being lowered into mass graves in New York City circulated on social media as the city responded to the COVID-19 pandemic. The images and related video footage are accurate depictions of recent burials on Hart Island in the Long Island Sound. That said, there have been some misconceptions about the mass graves. Posts about the grave site were flagged as part of Facebook’s efforts to combat false news and misinformation on its News Feed. (Read more about our partnership with Facebook.) First, mass burials didn’t begin on Hart Island during the COVID-19 pandemic. The city has used the location as a public cemetery for over 150 years, burying unclaimed people and those whose loved ones can’t afford private burials. Second, not all locals who die from COVID-19 are being buried there, as some posts have suggested. The site is still designated for deceased people with no known next of kin. But as the city struggles with the mounting death toll amid the pandemic, burials on the island have dramatically increased in recent weeks. There are usually about 25 burials on the island each week, the New York mayor’s press secretary Freddie Goldstein told CNN. But that number has climbed to nearly 25 each day. The island’s interment operation is managed by the city’s Department of Correction, and inmates usually assist in the burials. But that has changed since the pandemic. DOC spokesperson Jason Kersten has said that city inmates are not currently involved with the burials: ""For social distancing and safety reasons, city-sentenced people in custody are not assisting in burials for the duration of the pandemic. Contracted laborers are performing this important work under DOC supervision,"" according to a report by the Gothamist. Bodies are ordinarily held at the city’s morgues anywhere from 30 to 60 days, Goldstein said. But to make room for the influx of deceased individuals during the pandemic, the city’s medical examiner’s office announced a new policy of holding unclaimed bodies for only up to 15 days before they are transferred to the island. New York City’s Hart Island has been used as a public cemetery for unclaimed bodies since the 1800s, but the city’s staggering death toll amid the COVID-19 pandemic has dramatically increased the number of burials on the island. Social media posts about the burials are mostly accurate, but many need additional information."

Ex Output:

Images show COVID-19 victims being buried in mass graves in New York City.